The market expansion is primarily fueled by the increasing incidence of venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE), and other blood-clotting disorders worldwide.
Clinicians are reminded to include non-prescription supplement history when evaluating thrombotic events in younger adults ...
In honor of World Thrombosis Day (WTD), a disease awareness campaign sponsored by the International Society on Thrombosis and Haemostasis (ISTH), Stago presents a special educational event. The ...
Since its introduction to clinical use, the D-dimer test for deep venous thrombosis/pulmonary embolism has been a blessing and a curse. What is the current thinking regarding D-dimer use in clinical ...
Phase I Dose Escalation, Pharmacokinetic and Pharmacodynamic Study of Naptumomab Estafenatox Alone in Patients With Advanced Cancer and With Docetaxel in Patients With Advanced Non–Small-Cell Lung ...
Age-adjusted D-dimer cutoffs can safely rule out deep vein thrombosis (DVT) in many suspected cases, according to the ADJUST-DVT trial. For patients ages 50 and older with a nonhigh or unlikely ...
The growing prevalence of cardiovascular and thrombotic disorders is driving strong demand for D-dimer testing. As blood clot-related risk factors continue to increase, the need for precise diagnostic ...
China: A recent study published in Medicine highlights the clinical value of combining plasma D-dimer testing, color Doppler ...
Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The plasma D-dimer assay has been used, along with clinical prediction scores, to rule out ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results